DRUG DELIVERY药物递送
DRUG DELIVERY(英文缩写 DRUG DELIV),ISSN 1071-7544,eISSN 1521-0464,中文译名:药物递送 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-11-01 至 2026-10-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 6.819 | Q1 |
| 2022 | 6.000 | Q1 |
| 2023 | 6.500 | Q1 |
| 2024 | 8.100 | Q1 |
| 2025 | 8.000 | Q1 |
DRUG DELIVERY 最新收录文献
-
1. {"_":"Oral delivery of recombinant expressing an IL-23 inhibitor as a potential therapeutic strategy for experimental colitis.","i":["Lactococcus lactis"]}
1. {"_":"口服递送表达IL-23抑制剂的重组乳酸乳球菌作为实验性结肠炎的潜在治疗策略。","i":["乳酸乳球菌"]}PMID:日期:2026-10-03Interleukin 23 (IL-23) is a key mediator of immune-mediated intestinal inflammation and plays an important role in the pathogenesis of inflammatory bowel disease. Inhibition of IL-23 signaling has therefore been validated as a therapeutic target in IBD. Here, we tested small binding proteins of non-immunoglobulin origin targeting either the IL-23 cytokine p19 subunit or the IL-23 receptor subunit IL-23R, designated ILP and REX binders, respectively. ILP317 and REX115 variants of formerly identified protein collections were tested in murine experimental colitis. bacteria engineered for ILP317 or REX115 expression were administered to experimental mice via yogurt-coated food pellets before and during dextran sulfate sodium (DSS) and trinitrobenzenesulfonic acid (TNBS)-induced colitis. To compare both protein blockers, ILP317 and REX115 binders were administered intraperitoneally as soluble recombinant proteins. General health status, colon macroscopic and histological changes, mucosal tissue cell infiltration, local and systemic inflammatory cytokines were analyzed. In DSS- and TNBS-induced colitis, intraperitoneal administration of soluble ILP317 or REX115 reduced disease severity, including disease activity index, colon shortening, and mucosal inflammatory cell infiltration. Oral administration of recombinant expressing ILP317 also showed consistent protective effects, whereas oral expressing REX115 produced less pronounced effects in several experimental settings. Overall, ILP317 appeared more effective than REX115 when delivered orally by recombinant . Oral administration of non-colonizing expressing an IL-23p19 inhibitor may represent a promising preclinical strategy for the development of novel, non-invasive approaches to modulate intestinal inflammation.
-
2. Redefining intranasal brain delivery: from nasal entry to meaningful parenchymal and cellular exposure.
2. 重新定义鼻腔内脑部递送：从鼻腔进入到有意义的脑实质和细胞暴露PMID:日期:2026-10-01Nose-to-brain (N2B) delivery is a promising noninvasive strategy to circumvent the blood‒brain barrier (BBB). However, the clinical translation of N2B platforms remains hindered by a conceptual oversimplification that equates crude central nervous system (CNS) exposure with effective therapeutic delivery. This review reconceptualizes the N2B pathway as a stage-resolved sequential transport cascade extending from nasal entry to meaningful parenchymal and cellular access. We identify a critical imbalance in current formulation strategies, which have advanced two extreme poles, namely initial mucosal retention and epithelial permeation at one end and final target-cell engagement at the other, while leaving the intermediate post-epithelial gateways, including cerebrospinal fluid (CSF) and perivascular space (PVS)-mediated redistribution and deep intraparenchymal diffusion, as structural and interpretive blind spots. To bridge this gap, we propose an integrated engineering paradigm with three core design principles. First, multistage-aware design harmonizes sequential spatiotemporal functionalities within a single vehicle architecture. Second, disease-informed design integrates pathologically remodeled barrier states and glymphatic hydrodynamics into the formulation rationale. Third, cargo-informed design establishes the distinct biophysical identity and inherent liabilities of each payload, from small molecules to viral vectors and CRISPR machinery, as the primary engineering starting point. Finally, we advocate for a methodological standard demanding stage-specific validation of vehicle integrity, cross-boundary penetration, and functional target engagement, beyond compartment-blind whole-brain readouts. We further underscore the biofate and clearance of delivery systems as an emerging axis of safety and regulatory evaluation. Collectively, this framework provides a systematic basis for transitioning N2B engineering into a viable clinical modality.
-
3. Numerical simulation of PDRN iontophoresis: comparison with passive diffusion and key parameter analysis.
3. PDRN离子导入的数值模拟：与被动扩散的比较及关键参数分析PMID:日期:2026-09-25Polydeoxyribonucleotide (PDRN) is a bio-derived therapeutic agent known to exhibit regenerative, angiogenic, and anti-inflammatory effects. However, its relatively large molecular size limits penetration across the skin barrier, thereby reducing the feasibility of noninvasive transdermal delivery. Iontophoresis is a promising approach for enhancing the transport of charged macromolecules, yet quantitative understanding of PDRN iontophoresis remains limited. Here, we present an framework for cathodal PDRN iontophoresis based on the Nernst-Planck equation, focusing on passive diffusion and electromigration. The PDRN diffusion coefficient was determined from Franz diffusion cell experiments using the lag-time method, and the effective charge was estimated from prior experimental reports on dsDNA. A three-layer skin model comprising the stratum corneum, epidermis, and dermis was employed, and PDRN transport was analyzed as a function of applied current density, initial PDRN concentration, delivery time, and PDRN diffusion coefficient. Transport was quantified using molar flux and cumulative permeation at the epidermis-dermis interface and mid-dermis. The results clarify parameter-dependent regulation of delivery and reveal a depth-dependent shift in the dominant transport mechanism, highlighting the importance of iontophoresis for macromolecular delivery. Using calibrated outputs, we assessed agreement with experimental permeation data using the root-mean-square deviation (RMSD), mean absolute percentage error (MAPE), and the coefficient of determination (R). Overall, this work provides a computational baseline to predict PDRN iontophoresis outcomes and proposes practical iontophoresis strategies for PDRN to guide device design.
-
4. Bioengineered extracellular vesicles integrating anti-EphA2 recognition and oxaliplatin delivery for pancreatic cancer therapy.
4. 用于胰腺癌治疗的整合抗EphA2识别与奥沙利铂递送的生物工程细胞外囊泡PMID:日期:2026-09-22Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal solid tumors due to its dense desmoplastic stroma, poor vascular perfusion, and the limited intratumoral delivery of chemotherapeutic agents such as oxaliplatin (OXA). Extracellular vesicles (EVs) offer a biocompatible platform for drug delivery, yet their intrinsic lack of tumor specificity constrains therapeutic efficacy. Ephrin type-A receptor 2 (EphA2), which is highly expressed and efficiently internalized in PDAC, represents an attractive molecular target for guiding EVs into tumor cells. In this study, we engineered HEK293T-derived EVs to display membrane-anchored anti-EphA2 Fab fragments and encapsulate OXA (EVs-EphA2/OXA) as a targeted delivery system for PDAC therapy. Stable producer cells expressed the engineered Fab on the plasma membrane and released vesicles that retained canonical EV markers and robust antigen-binding capability. EVs-EphA2 demonstrated selective uptake into EphA2-positive AsPC-1 and BxPC-3 cells and induced significantly greater cytotoxicity than free OXA or untargeted EVs/OXA in vitro. In xenograft models, EVs-EphA2/OXA achieved the most pronounced tumor suppression, accompanied by increased γH2AX-associated DNA damage, enhanced TUNEL-positive apoptosis, and preferential tumor accumulation in biodistribution imaging. These findings demonstrate that EphA2-targeted EVs can substantially improve intratumoral delivery of OXA and amplify antitumor efficacy, supporting EVs-EphA2/OXA as a promising platform for receptor-guided chemotherapy in PDAC.
-
5. Nano spray-dried powders for efficient pulmonary delivery of proteins: an emphasis on comparisons of derived metrics determined by chapters <601> and <1604>.
5. 用于蛋白质高效肺部递送的纳米喷雾干燥粉末：重点比较由<601>和<1604>章确定的衍生指标PMID:日期:2026-09-15Pulmonary protein delivery has proven to be an effective approach for the treatment of local and systemic diseases, and particles that can be efficiently inhaled into peripheral regions should possess aerodynamic sizes of <2 µm, for which nano-spray-drying (NSD) is a powerful tool for fabrication. However, NSD powders have a high specific surface area and surface energy, which causes severe agglomeration and poor aerosolization performance. To solve these problems, cyclodextrin/leucine delivery systems were constructed, which can evidently protect alkaline phosphatases (AKP) with >94% of their biological activities retained in NSD powders and endow nanoparticle-based AKP-cyclodextrin-leucine (ACL) powders with improved aerosolization behavior. This can be evidenced by the fine particle (<4.46 µm) fraction (FPF) and FPF (in unit percentage), of only 49.9% and 18.7% for the leucine-free ACL0, while significantly increased to 82.1% and 33.1% for ACL15, and further increased to >88% and >41% for ACL30/ACL45. The USP Chapters of traditional <601> and newly published <1604> were employed to determine derived metrics for aerodynamic particle size distribution (APSD). It was demonstrated that the authenticity of fitted values calculated in Chapter <601> was severely influenced by APSD profiles, and the fitted values can have immense differences from the actual values determined in Chapter <1604> . The differences can be minimized when the APSD is unimodal and normal across sized impactor stages. Hence, the authenticity of the fitted values can be improved. These new data deepen the understanding of APSD analyses and generate insights into the improvement of value authenticity for derived metrics, henceforward facilitating continuous improvements in quality control of inhaled products.
-
6. Skin physiologically based pharmacokinetic modeling: current research progress, software comparison, and future perspectives.
6. 皮肤生理药代动力学建模：当前研究进展、软件比较与未来展望PMID:日期:2026-09-07Transdermal and topical delivery systems (TDS) have emerged as the third-largest route of administration due to their ability to bypass first-pass metabolism and maintain stable plasma concentrations. Skin physiologically based pharmacokinetic (PBPK) models mechanistically characterize the percutaneous absorption process, predict local and systemic exposure, and enhance research and development efficiency through virtual clinical trials. This paper first elaborates on the theoretical foundation of skin PBPK modeling based on Fick's second law of diffusion and compares the model assumptions and application scenarios of four well-established and validated modeling platforms: Simcyp, GastroPlus, Skin-CAD, and PK-Sim. The findings indicate that Simcyp provides a refined depiction of skin physiological structure and is widely applied in clinical evaluation and special population prediction. GastroPlus focuses more on the mechanistic description of TDS formulations. Skin-CAD, as a specialized software, is extensively utilized for extrapolation (IVIVE) predictions and formulation optimization. PK-Sim, as a freely accessible open-source software, has been used to investigate the physiological ontogeny of skin in pediatric populations. However, existing studies share limitations such as highly inconsistent model structures with varying complexity, challenges in acquiring accurate parameters, and a scarcity of physiological information for special populations. Future research should prioritize optimizing parameter acquisition methods and broadening physiological databases for pediatric, geriatric, and skin-lesion populations. Additionally, integrating non-invasive imaging technologies to construct high-precision 'digital twin' skin models represents a critical future direction. These advancements will drive the transition of PBPK models from descriptive tools to supportive instruments for individualized dosing and regulatory decision-making.
-
7. Microfluidic-engineered glucose-responsive microparticle depot for smart insulin delivery.
7. 微流控工程化葡萄糖响应性微粒储库用于智能胰岛素递送PMID:日期:2026-09-03Diabetes mellitus, chronic metabolic disease marked by persistent hyperglycemia resulting from inadequate insulin production or impaired action. Despite advancements in glucose-responsive insulin delivery systems, challenges persist such as limited responsiveness to dynamic glucose fluctuations, in vivo biocompatibility, and production scalability with uniform performance. However, insulin-loaded microspheres combined with microfluidics-based technology improve the subcutaneous insulin reservoir and homogeneous microsphere production rate. This study presents a microfluidic-engineered glucose-responsive controlled-insulin release microsphere using Glucose oxidase (GOx) as the glucose-sensing unit and a hybrid carrier composed of poly (lactic-co-glycolic acid) (PLGA) and acid-sensitive acetalated dextran (Ac-dex). The microfluidic-based fabrication method ensured uniform and controllable microsphere size and stable performance with satisfactory batch-to-batch reproducibility. In Streptozotocin (STZ)-induced diabetic mice, the microspheres maintained normal blood glucose levels for at least 20 hours. Absence of additional treatment-induced organ toxicity, systemic inflammation, and low hypoglycemic index ensured that the formulation is safe. Besides, this study provides a promising strategy for closed-loop insulin therapy, with potential clinical applications in improving glycemic control and reducing the burden of diabetes management.
-
8. Synergistic epigenetic modulation and ferroptosis induction via codelivery of Decitabine and Sorafenib for potent anti-tumor therapy.
8. 通过地西他滨和索拉非尼的共递送实现协同表观遗传调控与铁死亡诱导，用于强效抗肿瘤治疗PMID:日期:2026-09-03Despite considerable advances in cancer therapy, the intrinsic heterogeneity of malignant cells continues to compromise therapeutic efficacy with conventional monotherapies, driving the need for combination treatments to achieve more durable and complete responses. The limited efficacy of conventional chemotherapy is largely attributable to the immunosuppressive tumor microenvironment, which is frequently perpetuated by epigenetic mechanisms, including aberrant DNA methylation. To overcome these limitations, we hypothesized that Decitabine (Dac)-mediated sensitization could dramatically enhance Sorafenib (Sor)-induced ferroptosis, and to test this synergy, we developed an innovative biomimetic codelivery platform comprising polymer micelles loaded with Sor surface-coated with exosomes encapsulating Dac (Exo&PM/D + S). This platform facilitates codelivery, enabling Dac-mediated DNA hypomethylation to remodel the tumor microenvironment and promote Sor-triggered ferroptosis. , Exo&PM/D + S exhibited potent anti-tumor activity by concurrently enhancing DNA demethylation and ROS accumulation. In mouse neuroblastoma models, the system significantly suppressed tumor growth, stimulated antitumor immunity, and extended survival. Mechanistic studies confirmed that Dac potentiates Sor-induced ferroptosis through epigenetic modulation. Thus, Exo&PM/D + S represents a promising nanotherapeutic strategy that synergizes epigenetic modulation with ferroptosis induction for enhanced anti-tumor efficacy.
-
9. Sprayable NIR/pH-responsive NSC/PF127 hydrogel loaded with MoO₂, ciprofloxacin, and FGF-2 for enhanced antibacterial and pro-regenerative infected wound healing.
PMID:日期:2026-09-03Infected wounds represent a significant clinical burden owing to persistent infection, excessive inflammation, and impaired tissue regeneration. To overcome these limitations, we developed a sprayable -succinyl chitosan/Pluronic F127 (NSC/PF127) hydrogel incorporating MoO₂ nanoparticles, ciprofloxacin, and fibroblast growth factor-2 (FGF-2). At body temperature, the hydrogel rapidly transitions from a solution to a gel and responds to both pH changes and near-infrared (NIR) irradiation. MoO₂ exhibits NIR-mediated photothermal activity, while CIP and FGF-2 are released in a sustained and pH-dependent manner, thereby maintaining antibacterial efficacy and growth factor bioactivity. studies demonstrated excellent cytocompatibility and significantly enhanced fibroblast and keratinocyte migration. The combined photothermal effect and antibiotic therapy effectively suppressed bacterial growth and disrupted established biofilms. In a rat model of -infected full-thickness wounds, the hydrogel composite significantly accelerated healing, reduced inflammation, promoted collagen deposition and angiogenesis, and enhanced tissue regeneration. Biochemical and gene expression analyses further indicated reduced oxidative stress and improved tissue regeneration. This multifunctional, sprayable hydrogel combines targeted antibacterial action with sustained pro-regenerative signaling, offering a promising strategy for further preclinical investigations of infected wound management.
-
10. Analyzing the impact of subcutaneous injection needle, device, and administration characteristics on patient pain, anxiety, and safety: a systematic literature review.
10. 分析皮下注射针头、装置及给药特征对患者疼痛、焦虑和安全性影响：一项系统性文献综述PMID:日期:2026-08-27The subcutaneous (SC) injection route is a commonly used and important method for therapeutic delivery of a wide range of compounds, and needle characteristics have a significant influence on patient pain, anxiety, safety, and other outcomes. This systematic review evaluates the evidence on how needle-specific characteristics (e.g. gauge, length, tip design, wall thickness, concealment) and administration- or device-related factors can affect patient-reported outcomes and clinical safety indicators during and following SC injections. A comprehensive search was conducted in MEDLINE, PubMed, Embase, and ClinicalTrials.gov in June 2024. Studies were included if they assessed the relationship between needle characteristics and pain, anxiety, safety, or related outcomes in individuals receiving SC injections. A dual-reviewer process was used for study selection, data extraction, and quality assessment. Sixty-two studies met inclusion criteria. Evidence consistently indicated that thinner and shorter needles reduced patient-reported pain and adverse events such as bruising and bleeding. Tapered and lubricated needles, hidden or retractable needle designs, and use of autoinjectors or prefilled syringes also contributed to reduced anxiety and improved user satisfaction. However, results were heterogeneous, and many studies lacked sufficient power or single-variable evaluation of individual needle parameters, limiting definitive conclusions. Needle characteristics significantly influence patient experience and safety with SC delivery. While both clinical evidence and practical experience clearly favor thinner, shorter, and concealed needles, further standardized, high-quality research is needed to isolate and quantify the specific contributions of individual needle characteristics to optimize injection practices and support patient-centered device design.